PBM

+ Watchlist + Portfolio

Psyence Biomedical Ltd.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $5.16
52-Week Range: $1.92 – $175.78
Market Cap: $19.72M
P/E (TTM): —
EPS (TTM): -12.56
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.70
PEG Ratio: —
Return on Equity: -58.62%
Return on Assets: -31.33%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 14.62
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-4.96M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $12.24M

PBM Income statement, annual periods, in CAD
CAD	FY2023	FY2024	FY2025	FY2026
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.61M	$954.59K	$342.17K	$1.47M
Selling, General & Admin	$1.63M	$1.80M	$3.32M	$4.77M
Operating Expenses	$3.23M	$43.35M	$3.66M	$5.95M
Operating Income	-$3.23M	-$43.35M	-$3.66M	-$5.95M
EBITDA	-$3.21M	-$51.11M	$1.03M	-$6.92M
Pretax Income	-$3.21M	-$51.16M	$1.01M	-$6.94M
Net Income	-$3.21M	-$51.16M	$1.01M	-$6.94M
Diluted EPS	-940.02	-14274.29	32.76	—
Diluted Shares	3411	3584	30887	—

PBM Balance Sheet statement, annual periods, in CAD
CAD	FY2023	FY2024	FY2025	FY2026
Cash & Equivalents	$1.33M	$733.19K	$6.14M	$7.44M
Receivables	$149.37K	$41.75K	$137.35K	$362.76K
Current Assets	$1.59M	$1.13M	$6.56M	$9.11M
Total Assets	$1.59M	$1.13M	$7.32M	$17.57M
Current Liabilities	$1.79M	$12.10M	$594.37K	$623.19K
Total Debt	—	$10.45M	—	—
Total Liabilities	$1.79M	$12.10M	$594.37K	$623.19K
Retained Earnings	-$6.30M	-$57.46M	-$56.45M	-$63.38M
Shareholders' Equity	-$200.44K	-$10.97M	$6.72M	$16.94M
Working Capital	-$200.44K	-$10.98M	$5.97M	$8.49M
Net Debt	—	$9.71M	—	—

PBM Cash Flow statement, annual periods, in CAD
CAD	FY2023	FY2024	FY2025	FY2026
Operating Cash Flow	-$1.59M	-$2.95M	-$3.73M	-$8.14M
Capital Expenditure	—	-$5.73K	-$9.88K	-$500.23K
Free Cash Flow	-$1.59M	-$2.95M	-$3.74M	-$8.64M
Depreciation & Amortisation	$0.00	$240.00	$4.27K	$5.27K
Stock-Based Compensation	$221.29K	$317.88K	$0.00	$155.34K
Investing Cash Flow	$0.00	-$5.73K	-$16.23K	-$4.51M
Financing Cash Flow	$1.17M	$2.35M	$9.15M	$13.96M
Net Change in Cash	-$419.16K	-$601.09K	$5.40M	$1.31M

PBM Income statement, quarterly periods, in USD
USD	Q3 2025
Revenue	$0.00
Research & Development	$357.44K
Selling, General & Admin	$1.15M
Operating Expenses	$1.51M
Operating Income	-$1.51M
EBITDA	-$749.17K
Pretax Income	-$753.25K
Net Income	-$753.25K
Diluted EPS	-3.19
Diluted Shares	237044

PBM Balance Sheet statement, quarterly periods, in USD
USD	Q3 2025
Cash & Equivalents	$7.15M
Receivables	$174.19K
Current Assets	$7.63M
Total Assets	$12.81M
Current Liabilities	$943.07K
Total Liabilities	$943.07K
Retained Earnings	-$58.44M
Shareholders' Equity	$11.87M
Working Capital	$6.69M

Market Snapshot

About

Psyence Biomedical Ltd. is a life sciences company focused on developing psilocybin-based therapeutics for treating mental health conditions. The company conducts clinical trials investigating psilocybin for palliative care, end-of-life anxiety, treatment-resistant depression, and other psychiatric disorders.